If You Invested in Unity Btech (UNBX)

Unity Biotechnology, Inc. (trading under the symbol UNBX) is a former publicly traded company whose common stock, with a par value of $0.0001 per share, was previously listed on The Nasdaq Stock Market LLC. According to its SEC filings, the company’s common stock was suspended from trading on Nasdaq and later delisted following the filing of a Form 25 by Nasdaq with the Securities and Exchange Commission. After the delisting became effective, the company’s common stock traded on the OTC Pink Limited Market under the symbol UNBX.

Unity Biotechnology, Inc. reported its principal executive offices as being located in Foxborough, Massachusetts. The company’s SEC filings identify it as a registrant under the Securities Exchange Act of 1934, with its common stock registered pursuant to Section 12(b) of the Act prior to the delisting. The company used its SEC reports, including Forms 8-K and Form 15, to communicate material corporate events and changes in its reporting status.

A key development in the company’s history was the decision to pursue a Plan of Complete Liquidation and Dissolution. In a special meeting of stockholders, Unity Biotechnology, Inc. presented a proposal for the liquidation and dissolution of the company under the General Corporation Law of the State of Delaware. Stockholders approved the dissolution proposal and the related Plan of Dissolution, granting the board of directors authority and discretion to proceed with the dissolution in accordance with Delaware law and the plan.

Following stockholder approval, Unity Biotechnology, Inc. filed a Certificate of Dissolution with the Secretary of State of Delaware. The Certificate of Dissolution became effective as of a specified time on September 26, 2025. From the effectiveness of the Certificate of Dissolution, the company’s stock transfer books were closed, and shares of common stock were no longer assignable or transferable on the company’s books, other than in limited circumstances such as transfers by will, intestate succession, operation of law, or upon dissolution of a record holder or its successors. After dissolution, stockholders’ rights and obligations are governed by the provisions of Delaware law applicable to dissolved corporations.

In connection with its wind-down, Unity Biotechnology, Inc. entered into a Lease Termination Agreement and Amendment for its office and laboratory space. The agreement provided for the early termination of a lease that had originally been scheduled to run for several more years. As part of the lease termination, the company agreed to certain payments and arrangements with its landlord, and it also entered into a Sublease Termination Agreement with a subtenant related to the same premises. The lease termination was described by the company as being consistent with its plan to reduce operating costs and implement the approved dissolution and liquidation.

The company also disclosed that, prior to these steps, it had implemented a plan to reduce operating costs and preserve capital, which included a reduction in force affecting all of the company’s employees. These actions, together with the approval and implementation of the Plan of Dissolution, indicate that Unity Biotechnology, Inc. transitioned from an operating business into a dissolved Delaware corporation focused on liquidating its assets and satisfying its obligations in accordance with the plan and applicable law.

Subsequently, Unity Biotechnology, Inc. filed a Form 15 with the SEC. In this filing, the company certified and gave notice of the termination of registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934 and the suspension of its duty to file reports under Sections 13 and 15(d) of the Act. The Form 15 identified the class of securities covered as common stock, par value $0.0001 per share, and indicated that there were a limited number of holders of record as of the certification or notice date. The filing relied on specific Exchange Act rules to terminate or suspend reporting obligations.

Because of these steps—delisting from Nasdaq, trading on the OTC Pink Limited Market, stockholder approval of a Plan of Complete Liquidation and Dissolution, filing of a Certificate of Dissolution, and the subsequent Form 15—Unity Biotechnology, Inc. is best understood in the context of a dissolved, former public company rather than an ongoing operating enterprise. Its SEC filings provide a record of the transition from active trading on a national securities exchange to dissolution and the winding up of its affairs.

Trading history and status of UNBX stock

Unity Biotechnology, Inc.’s common stock was at one time registered under Section 12(b) of the Exchange Act and traded on The Nasdaq Stock Market LLC. An 8-K filing explains that the company’s common stock was suspended from trading on Nasdaq on July 9, 2025, and that on August 6, 2025, Nasdaq filed a Form 25 with the SEC to delist the shares of common stock. The delisting became effective on August 16, 2025. The same filing states that deregistration of the shares under Section 12(b) of the Exchange Act would be effective after a specified period following the Form 25 filing date, subject to SEC determination.

The company further disclosed that, after the Nasdaq suspension and delisting, its common stock traded on the OTC Pink Limited Market maintained by OTC Markets Group, Inc. under the symbol UNBX. Later, by filing Form 15, Unity Biotechnology, Inc. sought to terminate registration of its common stock under Section 12(g) and to suspend its duty to file periodic reports under Sections 13 and 15(d). This sequence of events frames UNBX as a security that moved from a national exchange to the OTC Pink market and then toward deregistration and dissolution.

Dissolution and liquidation process

According to Unity Biotechnology, Inc.’s 8-K filings, the board of directors determined that it was in the best interests of the company and its stockholders that the company be dissolved. The board approved the voluntary dissolution under Delaware law pursuant to a Plan of Complete Liquidation and Dissolution and sought stockholder approval for this course of action. At a special meeting of stockholders, the company presented a dissolution proposal and an adjournment proposal related to the special meeting. Voting results reported in the 8-K show that stockholders approved both proposals, thereby authorizing the board to proceed with the liquidation and dissolution in accordance with the Plan of Dissolution.

Following stockholder approval, Unity Biotechnology, Inc. filed a Certificate of Dissolution with the Secretary of State of Delaware, which became effective on September 26, 2025. The company’s filings state that, from and after the effectiveness of the Certificate of Dissolution, stockholders have only such rights and obligations as provided under Delaware law for stockholders of a dissolved corporation. The company also disclosed that it closed its transfer books as of the effective time of the Certificate of Dissolution, limiting further transfers of its common stock on its books to specific circumstances.

Key corporate actions related to wind-down

In addition to the formal dissolution steps, Unity Biotechnology, Inc. reported several actions aligned with its wind-down. The company entered into a Lease Termination Agreement and Amendment with its landlord concerning its office and laboratory space. The original lease term had been scheduled to run for several additional years, but the Lease Termination Agreement provided for an early termination date, with the possibility of acceleration at the landlord’s option. As consideration, the company agreed to pay amounts described as prepaid rent and to allow the landlord to draw on a letter of credit, as detailed in the 8-K summary.

The company also entered into a Sublease Termination Agreement with a subtenant, terminating a sublease for the same office and laboratory space. Under that agreement, the subtenant made a payment to the company and granted the company the right to draw down a letter of credit, with the proceeds to be paid to the landlord under the terms of the Lease Termination Agreement. The 8-K explains that these arrangements were part of the company’s effort to terminate its lease obligations in light of the dissolution plan.

Earlier disclosures referenced in the 8-K indicate that the company had implemented a plan to reduce operating costs and preserve capital, including a reduction in force affecting all of its employees. These measures, combined with the lease and sublease terminations and the formal dissolution process, illustrate the steps Unity Biotechnology, Inc. took to wind up its affairs as a dissolved Delaware corporation.

UNBX as a defunct public company

Given the filing of a Certificate of Dissolution, closure of the stock transfer books, approval of a Plan of Complete Liquidation and Dissolution, and the subsequent Form 15 to terminate registration and suspend reporting obligations, Unity Biotechnology, Inc. is no longer operating as an active, reporting public company. Its remaining activities, as reflected in the filings, relate to liquidation of assets, satisfaction of obligations, and administration of the dissolution process under Delaware law and the Plan of Dissolution.

Investors researching UNBX should understand that the company’s own filings caution that trading in its securities is highly speculative and poses substantial risks. The company noted that trading prices for its securities may bear little or no relationship to any value ultimately realized by holders, and it urged extreme caution with respect to existing and future investments in its securities. These statements underscore that UNBX represents the equity of a dissolved corporation in the process of liquidation rather than a going concern.